learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
Search
for
Did you mean Kintor Pharmaceuticals?
Learn
5 / 801 resultslearn Kopexil
learn Hinokitiol
learn TeraCeutic™
learn Kumquat fruit extract
Research
5 / 405 results
research Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation
Collaboration and innovation are key to developing effective, safe hair loss treatments.
research Trace elements content and hormonal profiles in women with androgenetic alopecia
Women with AGA have more androstenedione and dihydrotestosterone, less copper and zinc; copper imbalance affects AGA; treatment improves hormones and minerals.
research A Study to Evaluate the Efficacy of Baicapil Formulations in Treatment of Telogen Effluvium
Baicapil was effective in reducing hair loss and increasing hair growth in women with telogen effluvium.
research Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?
Investing in a longevity megafund can help pension funds reduce longevity risk.
research Development and Validation of Androgen-induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents
The mouse models are effective for testing new hair loss treatments.
Community Join
5 / 407 resultscommunity Kintor Pharmaceutical’s KX-826 Shows Promising Results in Hair Loss Study
Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.
community Kintor Pharmaceutical Announced U.S. FDA Has Greenlighted Phase II Clinical Trial for Pyrilutamide to Treat Androgenetic Alopecia
Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.
community Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
community Pyrilutamide kintor pharmaceutical
The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.